Last reviewed · How we verify
NCT07234045
A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms
Phase 1 trial testing CAR T cells chimeric antigenreceptor cells in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma in 30 participants. Not yet recruiting.
30 December 2027
Quick facts
| Lead sponsor | Institute of Hematology & Blood Diseases Hospital, China |
|---|---|
| Phase | Phase 1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 30 November 2025 |
| Primary completion | 30 December 2027 |
| Estimated completion | 30 June 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- CAR T cells chimeric antigenreceptor cells — full drug profile →
Conditions studied
- Relapsed/Refractory B-cell Non-Hodgkin Lymphoma — all drugs for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma →
- Relapsed/Refractory B-cell ALL — all drugs for Relapsed/Refractory B-cell ALL →
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Who can join
Adults 18 to 75, any sex, with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or Relapsed/Refractory B-cell ALL. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A Clinical Study to Explore the Safety, Efficacy and Cellular Metabolic Kinetics of CT1195E CAR-T Cells Injection in Patients with Relapsed/Refractory B-Cell Neoplasms
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07234045
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Currently open trials in the same condition.
- NCT07376642 — A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, · EARLY_PHASE1 · recruiting
- NCT07073833 — The Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymphoma · Phase 1 · recruiting
- NCT06561425 — A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma · Phase 1, PHASE2 · active not recruiting
Other Institute of Hematology & Blood Diseases Hospital, China trials
Trials by the same sponsor.
- NCT06991920 — Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage · NA · not yet recruiting
- NCT07407010 — BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM · Phase 1 · not yet recruiting
- NCT07407140 — VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML · Phase 3 · not yet recruiting
- NCT07454226 — ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL · NA · not yet recruiting
- NCT07490288 — Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07234045 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institute of Hematology & Blood Diseases Hospital, China
- Last refreshed: 18 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07234045.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing